These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 24415364)

  • 41. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report.
    Maugars Y; Guillot P; Glémarec J; Berthelot JM; Le Goff B; Darrieutort-Laffite C
    J Med Case Rep; 2020 Aug; 14(1):130. PubMed ID: 32792004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
    J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility of extended dosing intervals of denosumab.
    Kettle JK; Patel PB
    J Oncol Pharm Pract; 2018 Jul; 24(5):343-347. PubMed ID: 28393590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
    Uhm SJ; Hall JA; Herrington JD
    J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resorptive hypercalcemia in post-essential thrombocythemia myelofibrosis: treatment with denosumab.
    Khoury N; Chang J; Gru AA; Whyte MP
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3051-5. PubMed ID: 22730513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Life-threatening hypocalcaemia associated with denosumab in advanced chronic kidney disease.
    Killen JP; Yong K; Luxton G; Endre Z
    Intern Med J; 2016 Jun; 46(6):746-7. PubMed ID: 27257154
    [No Abstract]   [Full Text] [Related]  

  • 49. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.
    Reagan P; Pani A; Rosner MH
    Am J Kidney Dis; 2014 Jan; 63(1):141-7. PubMed ID: 24021907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Refractory hypercalcemia in patient with lung cancer].
    Grzywacz A; Dziuk M; Niemczyk S
    Pol Merkur Lekarski; 2014 Apr; 36(214):261-4. PubMed ID: 24868900
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
    Saito Y; Takekuma Y; Komatsu Y; Sugawara M
    Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
    Autio KA; Farooki A; Glezerman IG; Chan A; Schneider CW; Barr HC; Seyboth BM; Kampel LJ; Danila DC; Rathkopf DE; Slovin SF; Scher HI; Morris MJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):e305-e309. PubMed ID: 25559408
    [No Abstract]   [Full Text] [Related]  

  • 53. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
    Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
    J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypercalcemia after discontinuation of long-term denosumab treatment.
    Koldkjær Sølling AS; Harsløf T; Kaal A; Rejnmark L; Langdahl B
    Osteoporos Int; 2016 Jul; 27(7):2383-2386. PubMed ID: 27098536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe hypercalcemia following denosumab treatment in a juvenile patient.
    Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
    J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful Use of Denosumab for Life-Threatening Hypercalcemia in a Pediatric Patient with Primary Hyperparathyroidism.
    Mamedova E; Kolodkina A; Vasilyev EV; Petrov V; Belaya Z; Tiulpakov A
    Horm Res Paediatr; 2020; 93(4):272-278. PubMed ID: 32998142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use and safety of denosumab in cancer patients.
    Manzaneque A; Chaguaceda C; Mensa M; Bastida C; Creus-Baró N
    Int J Clin Pharm; 2017 Jun; 39(3):522-526. PubMed ID: 28382583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
    Seisa MO; Nayfeh T; Hasan B; Firwana M; Saadi S; Mushannen A; Shah SH; Rajjoub NS; Farah MH; Prokop LJ; Wang Z; Fuleihan GE; Drake MT; Murad MH
    J Clin Endocrinol Metab; 2023 Feb; 108(3):585-591. PubMed ID: 36545700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Organic anxiety in a woman with breast cancer receiving denosumab.
    Lin KF; Chen KH; Huang WL
    Gen Hosp Psychiatry; 2015; 37(2):192.e7-8. PubMed ID: 25772947
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
    Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
    Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.